Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Funda Meric-Bernstam.
Cancer | 2005
Allen M. Chen; Funda Meric-Bernstam; Kelly K. Hunt; Howard D. Thames; Elesyia D. Outlaw; Eric A. Strom; Marsha D. McNeese; Henry M. Kuerer; Merrick I. Ross; S. Eva Singletary; Fredrick C. Ames; Barry W. Feig; Aysegul A. Sahin; George H. Perkins; Gildy Babiera; Gabriel N. Hortobagyi; Thomas A. Buchholz
The appropriate selection criteria for breast‐conserving therapy (BCT) after neoadjuvant chemotherapy are poorly defined. The purpose of the current report was to develop a prognostic index to help refine selection criteria and to serve as a general framework for clinical decision‐making for patients treated by this multimodality approach.
Cancer | 2005
Neslihan Cabioglu; Kelly K. Hunt; Thomas A. Buchholz; M.P.H. Nadeem Q. Mirza M.D.; S. Eva Singletary; Henry M. Kuerer; Gildy V. Babiera; Frederick C. Ames; Aysegul A. Sahin; Funda Meric-Bernstam
The risk of ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is associated with treatment and tumor‐related variables, such as surgical margin status and the use of systemic therapy, and these variables have changed over time. Correspondingly, the authors of the current study hypothesized that the contemporary multidisciplinary management of breast carcinoma would lead to an improvement in IBTR rates after BCT.
Cancer | 2004
Katja Goldflam; Kelly K. Hunt; Jeffrey E. Gershenwald; S. Eva Singletary; Nadeem Mirza; Henry M. Kuerer; Gildy V. Babiera; Frederick C. Ames; Merrick I. Ross; Barry W. Feig; Aysegul A. Sahin; Banu Arun; Funda Meric-Bernstam
Women with unilateral breast carcinoma are at increased risk for developing contralateral breast carcinoma (CBC). The authors sought to identify predictors of malignant or moderate to high‐risk histologic findings in contralateral prophylactic mastectomy (CPM) specimens, and to determine the efficacy of CPM.
Cancer | 2005
Anees B. Chagpar; Lavinia P. Middleton; Aysegul A. Sahin; Funda Meric-Bernstam; Henry M. Kuerer; Barry W. Feig; Merrick I. Ross; Frederick C. Ames; S. Eva Singletary; Thomas A. Buchholz; Vincente Valero; Kelly K. Hunt
The ideal pathologic assessment of sentinel lymph nodes (SLNs) in patients with breast carcinoma remains controversial. The authors evaluated how detailed assessment of SLNs using immunohistochemistry (IHC) and serial sectioning would affect treatment decisions and outcomes in patients with breast carcinoma who had negative SLNs on standard hematoxylin and eosin staining.
Cancer | 2004
Jeannie Shen; Kelly K. Hunt; Nadeem Q. Mirza; Savitri Krishnamurthy; S. Eva Singletary; Henry M. Kuerer; Funda Meric-Bernstam; Barry Feig; Merrick I. Ross; Frederick C. Ames; Gildy V. Babiera
Breast carcinoma with intramammary lymph node (intraMLN) metastases is considered to be Stage II disease, even in the absence of axillary lymph node involvement. Nonetheless, little is known regarding the clinical significance of intraMLN metastases. The goals of the current retrospective analysis were to elucidate the clinical relevance of intraMLN metastases and to assess the relation between such metastases and outcome in patients with breast carcinoma.
Cancer | 2004
Tina W. F. Yen; Kelly K. Hunt; M.P.H. Nadeem Q. Mirza M.D.; Eva S. Thomas; S. Eva Singletary; Gildy V. Babiera; Funda Meric-Bernstam; Thomas A. Buchholz; Barry W. Feig; Merrick I. Ross; Frederick C. Ames; L D O Richard Theriault; Henry M. Kuerer
To date, the impact of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐24 trial reported in 1999 on the use of tamoxifen after surgery for ductal carcinoma in situ (DCIS) is unknown. The current study was designed to evaluate the impact of NSABP B‐24 on current practices at a comprehensive cancer center.
Cancer | 2005
Jeannie Shen; Kelly K. Hunt; M.P.H. Nadeem Q. Mirza M.D.; Thomas A. Buchholz; Gildy V. Babiera; Henry M. Kuerer; Isabelle Bedrosian; Merrick I. Ross; Frederick C. Ames; Barry W. Feig; S. Eva Singletary; Massimo Cristofanilli; Funda Meric-Bernstam
In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of systemic recurrence and disease‐specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR.
Cancer | 2004
M.P.H. Timothy M. Pawlik M.D.; P.A.-C. Allison Perry M.S.; Eric A. Strom; Gildy V. Babiera; Thomas A. Buchholz; Eva Singletary; George H. Perkins; Merrick I. Ross; Naomi R. Schecter; Funda Meric-Bernstam; Frederick C. Ames; Kelly K. Hunt; Henry M. Kuerer
Balloon catheter–based accelerated partial breast irradiation (APBI) is an alternative to whole‐breast external‐beam irradiation during breast‐conserving therapy (BCT) for breast carcinoma, but it is limited by the size of the segmental mastectomy cavity. There are scant data on the average or optimal volume of resection (VR) in BCT. The objective of the current study was to evaluate the percentage of patients who would be eligible for balloon catheter–based APBI based on the selection criteria of the American Society of Breast Surgeons and the surgical VR.
Cancer | 2005
Karen H. Shahar; Thomas A. Buchholz; Ebrahim Delpassand; Aysegul A. Sahin; Merrick I. Ross; Fredrick C. Ames; Henry M. Kuerer; Barry W. Feig; Funda Meric-Bernstam; Gildy V. Babiera; S. Eva Singletary; S P A Jeri Akins; Nadeem Q. Mirza; Kelly K. Hunt
Radiation to the internal mammary chain (IMC) may be indicated for breast carcinoma patients with positive axillary sentinel lymph nodes (SLNs) and lymphoscintigraphic evidence of drainage to the IMC. The purpose of this study was to identify predictors of IMC drainage in patients with positive axillary SLNs.
Cancer | 2006
Linda J. Adepoju; W. Fraser Symmans; Gildy V. Babiera; S. Eva Singletary; Banu Arun; Nour Sneige; Lajos Pusztai; Thomas A. Buchholz; Aysegul Sahin; Kelly K. Hunt; Funda Meric-Bernstam; Merrick I. Ross; Frederick C. Ames; Henry M. Kuerer
The purpose of the study was to determine the risk of ipsilateral breast carcinoma recurrence (IBCR) and contralateral breast carcinoma (CBC) development in patients with a concurrent diagnosis of ductal carcinoma in situ (DCIS) with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS).